Vertex Pharmaceuticals (VRTX) Q3 2024 Earnings
Vertex Pharmaceuticals reported Q3 2024 revenue of $2.8B, beat analyst consensus of $2.7B by $86.4M. Diluted EPS came in at $4.38, beat the $4.14 consensus by $0.24. Vertex Pharmaceuticals reports across 3 business segments, led by Cystic Fibrosis (CF), Hematology and Pain Management, and Specialty Pipeline Programs.
Financial Snapshot
Trailing eight quarters through Q3 2024
Q3 2024 Earnings FAQ
Common questions about Vertex Pharmaceuticals's Q3 2024 earnings report.
Vertex Pharmaceuticals (VRTX) reported Q3 2024 earnings on November 4, 2024 after market close.
Vertex Pharmaceuticals reported revenue of $2.8B and diluted EPS of $4.38 for Q3 2024.
Revenue beat the consensus estimate of $2.7B by $86.4M. EPS beat the consensus estimate of $4.14 by $0.24.
You can read the 10-Q periodic report (0000875320-24-000223) directly on SEC EDGAR. The filing index links above go to sec.gov.